Targeting therapy in pemphigus: Where are we now and where are we going?

Pemphigus is a heterogeneous group of autoimmune skin disorders characterized by blistering of the skin and mucosal membranes, potentially affecting the quality of life if left unchecked. The current mainstay of treatment is systemic corticosteroids and immunosuppressive agents. Nevertheless, long-term use of these drugs can easily cause infections and other life-threatening adverse reactions. Thus, currently, researchers are trying to develop new and safer therapeutic approaches. Specifically, targeted therapies to pathogenic immune pathways have been gradually introduced and used for the treatment of pemphigus or in clinical trials, such as monoclonal antiCD20 antibody, BAFF inhibitor, BTK inhibitor, CAAR-T therapy, FcRn antagonist, and TNF-& alpha; inhibitor. In addition, IL-4R & alpha; antibody, IL-17 blockade, mTOR pathway inhibitor, CTLA-4Ig, and p38 MAPK inhibitors are theoretically promising treatment for pemphigus. Here, we review the research progress on the mechanism of targeted therapies for pemphigus.

Automated summary

Pemphigus refers to a group of autoimmune skin disorders characterized by blistering, which can negatively impact quality of life. The current standard treatment involves the use of systemic corticosteroids and immunosuppressive agents, but their long-term use can lead to serious side effects. Therefore, researchers are exploring new and safer therapeutic approaches.